Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

RA-ILD: Tocilizumab versus Rituximab

Comparative Effectiveness of Tocilizumab vs Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial

CHEST

Citation & Authors

Chest. 2026;169(2):428–439.

Zewen Wu; Po-Cheng Shih; Shiow-Ing Wang; Gema Hernández Ibarburu; Qing-Wen Wang; James Cheng Chung Wei; Liyun Zhang

ABSTRACT · RESEARCH SUMMARY

Research summary

After matching, each group included 1,194 patients with RA-ILD. There was no significant difference in 5-year all-cause mortality (HR 1.073; 95% CI 0.881–1.305), and hospitalization and mechanical ventilation were also similar. However, sensitivity analyses in patients with high baseline inflammatory markers found higher mortality and ventilation risks with tocilizumab. A nonsignificant overall difference does not establish identical efficacy, and the subgroup signals require validation.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗

Key findings

After matching, each group included 1,194 patients. The difference in 5-year all-cause mortality was not statistically significant (HR 1.073; 95% CI 0.881–1.305).

A nonsignificant difference does not establish equivalence. Risk signals in the subgroup with high inflammatory markers should be interpreted alongside the limitations of the original study.

CHEST Editor's Choice: Introduction to Reading Journals ↗